These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27052571)

  • 1. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
    Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
    Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
    Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
    Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses.
    Vardeu A; Davis C; McDonald I; Stahlberg G; Thapa B; Piotrowska K; Marshall MA; Evans T; Wheeler V; Sebastian S; Anderson K
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
    Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
    Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
    Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
    Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
    Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
    PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.
    Erkes DA; Xu G; Daskalakis C; Zurbach KA; Wilski NA; Moghbeli T; Hill AB; Snyder CM
    Mol Ther; 2016 Aug; 24(8):1444-55. PubMed ID: 27434584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model.
    Kwilas AR; Ardiani A; Dirmeier U; Wottawah C; Schlom J; Hodge JW
    Oncotarget; 2015 Sep; 6(29):28194-210. PubMed ID: 26317648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
    Xiao L; Joo KI; Lim M; Wang P
    PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
    McGray AJ; Hallett R; Bernard D; Swift SL; Zhu Z; Teoderascu F; Vanseggelen H; Hassell JA; Hurwitz AA; Wan Y; Bramson JL
    Mol Ther; 2014 Jan; 22(1):206-18. PubMed ID: 24196579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
    Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV
    Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.